Erythropoietin: When liability becomes asset in neurovascular repair

Maria B. Grant, Michael E. Boulton, Alexander V. Ljubimov

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.

Original languageEnglish (US)
Pages (from-to)467-470
Number of pages4
JournalJournal of Clinical Investigation
Volume118
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Erythropoietin
Oxygen
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Erythropoietin : When liability becomes asset in neurovascular repair. / Grant, Maria B.; Boulton, Michael E.; Ljubimov, Alexander V.

In: Journal of Clinical Investigation, Vol. 118, No. 2, 01.02.2008, p. 467-470.

Research output: Contribution to journalArticle

Grant, Maria B. ; Boulton, Michael E. ; Ljubimov, Alexander V. / Erythropoietin : When liability becomes asset in neurovascular repair. In: Journal of Clinical Investigation. 2008 ; Vol. 118, No. 2. pp. 467-470.
@article{9c28ff7cffb84c45833968e3a29ae225,
title = "Erythropoietin: When liability becomes asset in neurovascular repair",
abstract = "Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.",
author = "Grant, {Maria B.} and Boulton, {Michael E.} and Ljubimov, {Alexander V.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1172/JCI34643",
language = "English (US)",
volume = "118",
pages = "467--470",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Erythropoietin

T2 - When liability becomes asset in neurovascular repair

AU - Grant, Maria B.

AU - Boulton, Michael E.

AU - Ljubimov, Alexander V.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.

AB - Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.

UR - http://www.scopus.com/inward/record.url?scp=38849205803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849205803&partnerID=8YFLogxK

U2 - 10.1172/JCI34643

DO - 10.1172/JCI34643

M3 - Article

C2 - 18219388

AN - SCOPUS:38849205803

VL - 118

SP - 467

EP - 470

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -